ALK and non-small cell lung carcinoma: In a retrospective study, platinum/pemetrexed-based chemotherapy demonstrated modest efficacy (ORR: 29.7%, mDOR: 6.4 months) in patients with ALK-positive NSCLC who developed resistance to a second-generation ALK TKI[158].